Mercado mundial de tratamiento de la aracnoiditis: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado de tratamiento de la aracnoiditis

Se espera que el mercado mundial de tratamiento de la aracnoiditis experimente un crecimiento significativo durante el período de pronóstico. Esta afección es bastante común en personas de entre 40 y 60 años. Es una afección poco común y los factores de riesgo asociados incluyen el SIDA, la diabetes, el alcoholismo, la quimioterapia y el trasplante de órganos. La incidencia de aracnoiditis es baja; sin embargo, alrededor de 25.000 casos ocurren anualmente en América del Norte y del Sur, Asia y Europa. Un brote repentino de la pandemia de COVID-19 impuso estrictas regulaciones de bloqueo a nivel mundial, lo que provocó interrupciones en las actividades de importación y exportación del mercado mundial de tratamiento de la aracnoiditis.

Data Bridge Market Research analiza la tasa de crecimiento del mercado mundial de tratamiento de la aracnoiditis en el período de pronóstico 2022-2029. La CAGR esperada del mercado mundial de tratamiento de la aracnoiditis tiende a rondar el 3,50% en el período de pronóstico mencionado. El mercado se valoró en 2.300 millones de dólares en 2021 y crecería hasta 3.030 millones de dólares en 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

La aracnoiditis es un tipo de trastorno de la columna vertebral que se caracteriza por una inflamación crónica del tejido aracnoideo. Puede producirse debido a infecciones bacterianas, víricas o fúngicas de la aracnoides. En esta afección, el paciente suele experimentar dolor crónico en la parte baja de la espalda y las piernas. Los síntomas incluyen ardor en la parte inferior de las piernas, entumecimiento, hormigueo y, en algunas personas, esta afección provoca parálisis en las piernas. La prevalencia de esta enfermedad está aumentando y los procedimientos y tratamientos de diagnóstico importantes impulsarán el crecimiento del mercado.

Alcance y segmentación del mercado de tratamiento de la aracnoiditis

Global Arachnoiditis Treatment Market Dynamics

Drivers

• Increased Government Initiatives

Governments and numerous organizations take several initiatives to spread awareness about arachnoiditis that are estimated to boost the growth of the global arachnoiditis treatment market. For instance, the State of Michigan declared Arachnoiditis Awareness Month every year, aiming to create utmost awareness about the disease and its associated treatment, thus boosting the market growth.

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global polymyalgia rheumatic treatment market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.

Opportunities

• Increased Advanced Diagnostic Technology

Technological advancements and increased awareness about proper diagnosis of the disease are likely to boost the global arachnoiditis treatment market. Adoption of several diagnostic tools such as inflammatory markers and magnetic resonance imaging (MRI) are most likely to create opportunities for the global market. All these factors are also contributing in the growth of the market.  

• Increase in Elderly Population

Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global arachnoiditis treatment market over a forecast period.

• Unavailability of Appropriate Treatments

To treat rare conditions, many treatments are not available, especially in the under-developed countries. Severe patients needs to be treated with advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This global arachnoiditis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global arachnoiditis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Arachnoiditis Treatment Market

 During the pandemic, it has been witnessed that besides the pulmonary, renal, and hematological complications, gastrointestinal, there has been also a record of neurological appearances have also been reported frequently. Weakness, sensory deficit, autonomic dysfunction, sphincter dysfunction and ataxia were the most common neurological signs in the patients. Pathogenetic mechanisms responsible for developing spinal cord demyelinating diseases after SARS-CoV-2 infection may be either mediated by direct neurotropism or by unusual immune-mediated injury. Even though the pandemic is not there much, but the effect of this disease is still there. Thus, COVID-19 left a major impact on global arachnoiditis treatment market.

Global Arachnoiditis Treatment Market Scope

The global arachnoiditis treatment market is segmented on the basis of disease type, treatment, route of administration,end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

 (NSAIDs (non-steroidal anti-inflammatory drugs)

• Ibuprofen
• Naproxen
• diclofenac

Corticosteroids

• Aristocort.
• Bubbli-Pred
• Celestone
• Cortone Acetate

Anti-spasm drugs

• Dicycloverine
• Hyoscine
• Atropine
• Propantheline

Anti-convulsant drugs

• Carbamazepine
• Oxcarbazepine
• Lamotrigine

Disease Type

• Adhesive Arachnoiditis
• Arachnoiditis Ossificans
• Cerebral Arachnoiditis
• Hereditary Arachnoiditis
• Neoplastic Arachnoiditis
• Optochiasmatic Arachnoiditis

Treatment

• Pain Management
• Physiotherapy
• Psychotherapy
• Others 

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Arachnoiditis Treatment Market Regional Analysis/Insights

The global arachnoiditis treatment market is analysed and market size insights and trends are provided by disease type, treatment, route of administration,end-user, distribution channel as referenced above.

The major countries covered in the global arachnoiditis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period due to the high-income of the countries and advanced healthcare facilities. 

Asia-Pacific is dominating the market due to the increasing cases of cardiovascular diseases and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Arachnoiditis Treatment Market Share Analysis

The global arachnoiditis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global arachnoiditis treatment market.

Key players operating in the global arachnoiditis treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (Estados Unidos)
• Lilly (Estados Unidos)
• Amgen Inc. (Estados Unidos)
• Mallinckrodt plc (Reino Unido)
• Apotex Inc (Canadá)

SKU-54134